肠道菌群在结直肠癌中的研究进展

Research progress of gut microbiota in colorectal cancer

结直肠癌(CRC)作为最常见的恶性肿瘤之一,其发病率及病死率呈逐年上升趋势。而肠道菌群在CRC发生、发展及治疗中的作用成为近年的研究热点。人体中肠道菌群通过产生毒素及相关代谢产物与特异性受体结合、激活信号通路,从而刺激炎症因子释放,引起炎症反应,最终导致CRC的发生。益生菌可通过屏障作用、抑制DNA损伤等机制保护肠道黏膜,抵御CRC的发生,并可被用于预防及辅助治疗CRC。本文将对肠道菌群在CRC中的研究进展进行综述,并讨论肠道菌群可作为生物标志物在CRC治疗及诊断方面的最新发展。

Colorectal cancer(CRC)is one of the most common malignant tumors,and its incidence rate and mortality are increasing year by year.The role of gut microbiota in the occurrence,development,and treatment of colorectal cancer has become a research hotspot in recent years.The gut microbiota in the human body stimulates the release of inflammatory factors by producing toxins and related metabolites that bind to specific receptors and activate signaling pathways,causing an inflammatory response that ultimately leads to the occurrence of colorectal cancer.Probiotics can protect the intestinal mucosa and resist the occurrence of CRC through mechanisms such as barrier action and inhibition of DNA damage,and can be used for prevention and adjuvant treatment of CRC.T his article would review the res earch progress of gut microbiota in colorectal cancer and discuss the latest development of gut microbiota as a biomarker in the treatment and diagnosis of colorectal cancer.